Seagen Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, antibody-based therapeutics to fight various cancers. The company is an industry leader in antibody-drug conjugates, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)
Healthcare is a central component of our measure of Humankind Value, as a large contribution to modern life expectancies has come from the last 150 years of medical innovation. Seagen Inc. is responsible for positive Humankind Value. Considerable positive value is associated with Healthcare R&D ($33.1 B), Pharmaceuticals ($3.7 B), and Economic Value ($210.9 M). Positive value from Healthcare R&D and Pharmaceuticals contains our estimation of 763,383.0 additional years lived by people worldwide. Its economic value comes from offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. This firm can increase its Humankind Value by addressing Greenhouse Gases (-$78.7 M) and Air Pollution (-$16.4 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities.